Safety and Antisorptive Power of Ibandronate Applied in the Real-Life Setting
Narong Bunyaratavej MD*, Wiwat Wajanavisit MD**, Prayook Pauvilai MD***, Tassanee Kitumnuoypong MD****, Nipat Kittimanon MD*****, Songkiat Lektrakoon MD******
Affiliation : * Department of Orthopedic Surgery, Siriraj Hospital, Bangkok, Thailand ** Ramathibodi Hospital, Mahidol University, Bangkok, Thailand *** Lerdsin General Hospital, Ministry of Public Health, Bangkok, Thailand **** Rajavithi Hospital Ministry of Public Health, Bangkok, Thailand ***** Budhachinaraj Hospital Ministry of Public Health, Phitsanulok, Thailand ****** Sapprasithiprasong Hospital Ministry of Public Health, Ubon Ratchayhani, Thailand
This study involved 78 participants taking 150 mg of Ibandronate once a month for the investigation of the drug efficacy and safety. Ibandronate had a strong antiresorptive action that decreased 67.9 per cent of bone resorption. The total cases of unwanted effect were 21 that showed the common adverse events like other bisphosphonate. The most common events were flu-like symptom (8.75%) and dyspepsia (7.5%) which occurred at the first tablet. Most participants subsided after the following months, but only one case persisted in these symptoms through the study period while the others had a myalgia, diarrhea and burning of epigastric in percent of 6.25, 2.5, 1.25 respectively. Ibandronate (150mg) showed the strong antiresorptive effect and good compliance for taking once a month.
Keywords : Ibandronate
